Life Sciences
Background
The Decision Group has a track record in the Life Sciences industry, including working with the big pharma, medical device companies and biotech companies. The business landscape for companies in the life sciences in changing rapidly, forcing difficult decisions. Examples are how to create patient centered relations with your customers or how to generate growth with pricing pressures. The Decision Group, together with its academic links, provides an excellent combination of in-depth knowledge of life sciences and healthcare. We strongly believe that the key to an affordable healthcare includes a strong and responsible role of the life sciences industry.
Milestones
Dutch Life sciences Outlook 2010 & 2011
The Life Sciences Outlook is a monitor of the Dutch life sciences & health cluster, created in close collaboration between The Decision Group and Life Sciences Health.
The Decision Group’s monitoring methodology was used for the Dutch top sector plan for the Life Sciences cluster that was presented to the Dutch Ministry of Economics in June 2011.
Request your copy here.
Diagnostic study:
The study resulted in insight in the added value of diagnostics in healthcare and the increased ability to make reliable investment-decisions on diagnostics. We set up a framework , validated it in expert meetings with representatives of all stakeholders and applied the framework on a set of cases.
CEBR network:
The Decision Group is part of the CEBR network, the council of European BioRegions. The Decision Group participated in the Amsterdam and Cambridge meetings of this network, as well as a EU meeting.
Example of recent projects
Growth strategy for large pharma company
Developed the new growth strategy for the main product in the Netherlands. Project resulted in ROI of 200% within 5 months.
Pan-European service strategy for large medical device company
Developed a pan-European service strategy for maximizing extra revenue from services
Building future scenario’s for large pharma
Developed company specific scenario’s for the future and an action agenda to deal with the changes
Changing business model for large pharma
Developed new business model for large pharma to deliver more patient centred services
